title: Osteotropic polypeptide nanoparticles with dual hydroxyapatite binding properties and controlled cisplatin delivery.
abstract: OBJECTIVE
  Nanoparticles with prolonged residence time in bone constitute a valuable strategy for bone disease treatments. The aim of this work was to synthesise a simple nanoparticulate system exhibiting both anticancer and hydroxyapatite binding properties for potential bone cancer applications.
  
  
  METHODS
  The amphiphilic copolymer poly(γ-benzyl-glutamate)-block-poly(glutamic acid) (PBLG-b-PGlu) was synthetised by ring opening polymerization and nanoparticles were obtained by a simple nanoprecipitation method. Nanoparticles were characterized in terms of cisplatin interaction, association, and release as well as interaction with hydroxyapatite and their cytoxicity was studied in three prostate cancer cell lines.
  
  
  RESULTS
  PBLG-b-PGlu nanoparticles of ~50 nm in size were successfully prepared. They could display for the first time dual hydroxyapatite binding and anticancer properties mediated by the PGlu moiety. They could complex cisplatin at a drug loading content of 6.2% (w/w). Cisplatin release was triggered by physiological concentrations of chloride ions according to an almost zero order kinetics during 14 days. Simultaneously, these nanoparticles showed in vitro hydroxyapatite binding. Finally, they were shown to exert a cytotoxic effect in three prostate cancer cell lines that potentially metastasize to bone.
  
  
  CONCLUSIONS
  These properties suggest the potential utility of cisplatin-loaded PBLG-b-PGlu nanoparticles as carrier systems for the treatment of bone metastases.
authors.affiliation: Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, 5 rue Jean Baptiste Clément, 92296, Chatenay-Malabry, France, laura.de-miguel@u-psud.fr.
authors.forename: Laura
authors.initials: L
authors.lastname: de Miguel
authors.forename: Iuliana
authors.initials: I
authors.lastname: Popa
authors.forename: Magali
authors.initials: M
authors.lastname: Noiray
authors.forename: Eric
authors.initials: E
authors.lastname: Caudron
authors.forename: Ludovica
authors.initials: L
authors.lastname: Arpinati
authors.forename: Didier
authors.initials: D
authors.lastname: Desmaele
authors.forename: Gerardo
authors.initials: G
authors.lastname: Cebrián-Torrejón
authors.forename: Antonio
authors.initials: A
authors.lastname: Doménech-Carbó
authors.forename: Gilles
authors.initials: G
authors.lastname: Ponchel
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage* / Q000494:pharmacology; D003692:Delayed-Action Preparations / Q000737:chemistry*; D017886:Durapatite / Q000737:chemistry*; D006801:Humans; D008297:Male; D053758:Nanoparticles / Q000737:chemistry*; D011099:Polyglutamic Acid / Q000737:chemistry; D011467:Prostate / Q000187:drug effects / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D011099:Polyglutamic Acid; D017886:Durapatite; D002945:Cisplatin